The invention relates to a Thy1-SNCA. Construction method and application of Clu gene knockout mouse model

By constructing a Thy1-SNCA;Clu gene knockout mouse model and using the CRISPR/Cas9 system to knock out the Clu gene, the problem that existing PD models cannot fully simulate the pathological characteristics of PD was solved, enabling early appearance of PD symptoms and shortening the experimental cycle.

CN118979061AActive Publication Date: 2024-11-19JIANGHAN UNIVERSITY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411086460.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-19
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

Existing animal models of Parkinson's disease cannot fully simulate the motor and non-motor pathological features, and the experimental period is long, indicating that the models have defects.

Method used

By constructing a Thy1-SNCA;Clu gene knockout mouse model, the Clu gene was knocked out using the CRISPR/Cas9 system, which increased the accumulation of α-syn and shortened the time to onset of PD-like symptoms.

Benefits of technology

It shortens the time to onset of PD-like symptoms, improves the stability and pathological manifestations of the model, and shows obvious PD pathology earlier than traditional models, making it suitable for PD research and drug screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979061A_ABST
    Figure CN118979061A_ABST
Patent Text Reader

Abstract

The invention discloses a Thy1-SNCA (Selective Non-Networking Calibration). The invention discloses a construction method and application of a Clu gene knockout mouse model, and the construction method of the model comprises the following steps: hybridizing a Thy1-SNCA mouse and a Cu-KO mouse to obtain an F1 generation, and identifying to obtain Thy1-SNCA; a Cu <- / + > mouse; then carrying out SNCA on the Thy1; backcrossing the Cu- / + mouse and the Cu-KO mouse to obtain an F2 generation, and identifying to obtain a target genotype mouse, namely Thy1-SNCA; and Cu <- / -> mice. According to the invention, the Thy1-SNCA is constructed; the Cu <- / -> mouse can effectively shorten the occurrence time point of Parkinson-like dyskinesia, so that the experimental period is shortened, and more model mouse choices are provided for PD research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of Parkinson's disease research, and in particular to a method for constructing a Thy1-SNCA;Clu gene knockout mouse model and application thereof. Background Art

[0002] Parkinson's disease (PD) is the second most common neurodegenerative disease, characterized by motor and non-motor disorders. Pathological features include the loss of a large number of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies (LB). α-synuclein (α-syn, gene name SNCA) is the main component of LB.

[0003] At present, animal models of PD include: drug-induced neurotoxin models (such as MPTP, 6-OHDA, rotenone, etc.) and transgenic models (such as SNCA, Parkin, LRRK2, PINK1 and DJ-1). The MPTP model has the advantages of simple operation and selective damage to dopamine neurons. It can successfully replicate the characteristics of PD and is used in movement disorder research, but this model can only simulate movement disorders in PD and cannot simulate other non-motor symptoms. The 6-OHDA model can selectively destroy dopamine neurons and has a high dopamine neuron destruction effect. It is used in movement disorder research and drug screening, but this model will non-specifically destroy dopamine neurons and has a low survival rate. The Rotenone model can simulate mitochondrial dysfunction and oxidative stress, so it is used in mitochondrial function research, but it has the disadvantages of complex operation and low survival rate. In the SNCA transgenic model, the modification methods include mutations (A53T, A30P and E46K) or repeat fragments, which are helpful for studying α-nuclear protein-related degeneration and the relationship between genetic and environmental factors in PD, but some models have no significant dopaminergic neuron loss or show cell apoptosis forms inconsistent with human PD pathology. In the LRRK2 transgenic model, LRRK2 is a familial PD pathogenic gene, and its modification methods are mutations (G2019S and R1441C / G). It can be used for LRRK2 targeted drug testing and the study of LRRK2 function, but its disadvantages include motor defects but no obvious dopaminergic neuron loss and lack of LB pathological manifestations. In the Parkin transgenic model, mutation or knockout of ubiquitin ligase may lead to the accumulation of neurotoxic substrates. This model is useful for studying Parkin function, but phenotypic data is currently lacking. The DJ-1 gene knockout model can be effectively combined with the neurotoxin model. Although this model has motor defects, it has the problems of lack of LB pathological manifestations, no significant dopamine neuron loss, and little phenotypic data. In the PINK-1 transgenic model, PINK-1 is a neuroprotective kinase and its modification methods include mutation and knockout. For example, G309D-PINK1 mice can show dopamine reduction and motor defect phenotypes, but most PINK-1 models do not show a decrease in dopaminergic neurons and dopamine levels. It can be seen that the existing PD models have certain defects to varying degrees and cannot fully reflect the motor and non-motor pathological characteristics of PD.

[0004] Thy1-SNCA is one of the most widely used animal models of PD. It overexpresses human α-synuclein under the Thy1 promoter. Expression begins on the 10th day after birth. After 10 days, the expression of this protein increases steadily, but there are certain differences between different brain regions. In the hippocampus, the expression level of α-synuclein continues to increase from 2 to 6 months of age. In contrast, the expression of α-synuclein in the striatum decreases slightly or remains unchanged from 2 to 6 months of age, and the expression of this protein decreases by about 40% at 14 months of age. Tyrosine hydroxylase (TH) levels also decrease at 14 months of age, but only by about 20%. More importantly, the mortality and morbidity of Thy1-SNCA and the general health status are similar to those of wild-type mice before 14 months of age, and Parkinson's-like movement disorders are relatively obvious only at about 14 months of age. Summary of the invention

[0005] In view of the shortcomings of PD animal models in the prior art, the present invention aims to develop a new PD animal model with a short experimental period and stable pathological changes.

[0006] In order to achieve the above object, the technical solution of the present invention is as follows: The first aspect of the present invention provides a method for constructing a Thy1-SNCA;Clu gene knockout mouse model, comprising the following steps: The F1 generation was obtained by crossing Thy1-SNCA mice with Clu-KO mice, and Thy1-SNCA;Clu- / + mice were identified; The Thy1-SNCA;Clu- / + mice were backcrossed with Clu-KO mice to obtain the F2 generation, and the target genotype mice, namely Thy1-SNCA;Clu- / - mice, were identified.

[0007] In the construction method of the present invention, the Clu gene function of Clu-KO mice is lost compared to wild-type mice.

[0008] The inventors found that Clu can mediate the degradation of α-syn and relieve PD symptoms; and after completely knocking out Clu in mice, the aggregation of α-syn in the body can be increased. Based on this discovery, the inventors speculated that knocking out Clu is a key step to accelerate the occurrence of SNCA gene PD-like symptoms, and then established a Thy1-SNCA; Clu gene knockout mouse model. Experimental data show that the Thy1-SNCA; Clu gene knockout mouse model can show a large amount of tyrosine hydroxylase loss, a large amount of aggregated phosphorylated α-syn, and significant asymmetry of gait at 6 months of age, which is much earlier than the 14-month-old Thy1-SNCA mouse, thereby effectively shortening the experimental period.

[0009] Preferably, in the above construction method, Clu-KO mice lack the sequence shown in SEQ ID NO.1 relative to wild-type mice. The Clu gene is located on chromosome 14 and has five transcripts. In some embodiments of the present invention, Clu-KO mice are obtained by knocking out the exon E3-E4 region (the sequence is specifically shown in SEQ ID NO.1, with a total length of 2636 bp). The Clu-KO mice are hybridized with Thy1-SNCA mice and then backcrossed to obtain Thy1-SNCA; Clu gene knockout mice, which are superior to traditional animal models in terms of stability, pathology, behavioral characteristics, and time of occurrence, and have a high animal survival rate.

[0010] Preferably, in the above construction method, Clu-KO mice are constructed using the CRISPR / Cas9 system. In some embodiments of the present invention, the construction method of Clu-KO mice comprises the following steps: microinjecting the CRISPR / Cas9 system and the homologous recombination vector (Donor vector) into the fertilized eggs of female C57BL / 6N background mice, then transplanting the fertilized eggs into pseudo-pregnant female mice, waiting for them to become pregnant and give birth, and the recipient mice give birth to F0 generation mice, extracting genomic DNA for identification, and obtaining Clu-KO mice.

[0011] More preferably, in the CRISPR / Cas9 system, the gRNA target sequence is shown as SEQ ID NO.2 and SEQ ID NO.3.

[0012] More preferably, when the Clu-KO mouse lacks the sequence shown in SEQ ID NO.1, the Clu-KO mouse can be identified by the primer pair shown in SEQ ID NO.4 and SEQ ID NO.5; and when the product size is 514 bp, it is a Clu-KO mouse, and when the product size is 3150 bp, it is a wild-type mouse.

[0013] Preferably, in the above construction method, the primers used to identify Thy1-SNCA mice or Thy1-SNCA;Clu- / + mice include: a primer pair with sequences as shown in SEQ ID NOs. 7-8 and a primer pair with sequences as shown in 9-10.

[0014] Preferably, in the above construction method, the primers used to identify the target genotype mice include: a primer pair as shown in SEQ ID NO.7-8, a primer pair as shown in SEQ ID NO.9-10, a universal primer as shown in SEQ ID NO.4, and a reverse primer as shown in SEQ ID NO.5 or SEQ ID NO.6. Specifically, by extracting genomic DNA, performing PCR using the above primer pairs, respectively, retaining mice with both Thy1-SNCA and Clu- / - genotypes, mice of the target genotype are obtained.

[0015] The second aspect of the present invention provides the use of the Thy1-SNCA;Clu gene knockout mouse model constructed by the present invention in the preparation of a Parkinson's disease model. Through pathological and behavioral tests on the model, it was found that it can show a large amount of tyrosine hydroxylase loss, a large amount of aggregated phosphorylated α-syn, and significant asymmetry of gait at 6 months of age, which is more advantageous than the Thy1-SNCA model, so it can well replace the Thy1-SNCA mouse for PD research.

[0016] The third aspect of the present invention provides the application of the Thy1-SNCA;Clu gene knockout mouse model constructed by the present invention in exploring the function and mechanism of action of the SNCA gene.

[0017] The fourth aspect of the present invention provides the use of the Clu-KO mice constructed by the present invention in exploring the function, mechanism of action and molecular pathways involved in the Clu gene in nervous system diseases, and the use of Clu-KO mice as an animal model for drug screening with Clu as a molecular target.

[0018] Compared with the prior art, the beneficial effects of the present invention are: The inventors first discovered that Clu can mediate the degradation of α-syn and alleviate PD symptoms; based on this theoretical breakthrough, the inventors developed a new PD animal model, namely Thy1-SNCA;Clu- / - mice. Compared with the existing Thy1-SNCA mice, this model can effectively shorten the time point of the onset of Parkinson's-like movement disorders, thereby shortening the experimental period.

[0019] The Clu-KO mice provided by the present invention are preferably obtained by knocking out the exon E3-E4 region relative to wild-type mice. The Thy1-SNCA;Clu- / - mice obtained by hybridizing and backcrossing the Clu-KO mice with Thy1-SNCA mice are not only superior to traditional animal models in terms of time point, but also have obvious advantages in stability, pathology, behavioral manifestations, etc., and the animal survival rate is high.

[0020] The method of the present invention is simple and easy to implement and has a high survival rate. The obtained model can not only be used as a PD model, but also can be used to explore the role of SNCA and Clu in nervous system diseases, related mechanisms and possible involved molecular pathways; the present invention also provides a new animal model for drug screening with Clu as a molecular target. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Schematic diagram of the strategy for Clu-KO knockout mice in Example 1 of the present invention.

[0022] Figure 2 This is a diagram of PCR product detection of Clu-KO gene knockout mice in Example 1 of the present invention.

[0023] Figure 3 This is the sequencing result of the PCR product of the Clu-KO gene knockout mouse in Example 1 of the present invention.

[0024] Figure 4 This is the electrophoresis diagram for Thy1-SNCA genotype identification of F1 mice in Example 2 of the present invention.

[0025] Figure 5 This is the electrophoresis diagram for Thy1-SNCA genotype identification of F2 mice in Example 2 of the present invention.

[0026] Figure 6 This is the electrophoresis diagram for the identification of the Clu-KO genotype of the F2 generation mice in Example 2 of the present invention.

[0027] Figure 7 Graphs showing the ThS staining results of the striatum and substantia nigra compacta (SNc) of different mouse models at one month of age in Example 3 of the present invention.

[0028] Figure 8 This is a diagram showing the ThS staining results of the striatum and substantia nigra compacta in different mouse models at 3 months of age in Example 3 of the present invention.

[0029] Fig. 9 This is a diagram showing the ThS staining results of the striatum and substantia nigra compacta in different mouse models at 6 months of age in Example 3 of the present invention.

[0030] Fig.10 The immunofluorescence co-staining results of different mouse models at different ages in Example 3 of the present invention are shown.

[0031] Fig.11 These are the gait test results, open field test results, and rotarod test results of each mouse model in Example 4 of the present invention at 1 month of age.

[0032] Fig.12These are the gait test results, open field test results, and rotarod test results of each mouse model in Example 4 of the present invention at 3 months of age.

[0033] Fig.13 These are the gait test results, open field test results, and rotarod test results of each mouse model in Example 4 of the present invention at 6 months of age. DETAILED DESCRIPTION

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. The term "comprises" and any variations thereof in the specification and claims of the present invention are intended to cover non-exclusive inclusions.

[0035] In view of the shortcomings of PD animal models in the prior art, especially the problem that PD-like symptoms appear later in the Thy1-SNCA model, the present invention proposes the idea of ​​accelerating the occurrence of PD-like symptoms of the SNCA gene by knocking out Clu based on the new discovery that Clu can mediate α-syn degradation, and successfully constructs Thy1-SNCA; Clu- / - mice, and the construction method thereof comprises the following steps: (1) Construction of a Clu gene knockout mouse model, referred to as Clu-KO mouse; (2) The Thy1-SNCA mice were crossed with Clu-KO mice to obtain the F1 generation, and Thy1-SNCA;Clu- / + mice were identified; (3) The Thy1-SNCA;Clu- / + mice in the F1 generation were backcrossed with Clu-KO mice, and the target gene mice (Thy1-SNCA;Clu- / -) were obtained after identification.

[0036] In the above construction method, the rat tail alkali lysis method can be used for identification.

[0037] In the above construction method, Thy1-SNCA mice are existing PD models, which can be purchased directly through commercial channels or constructed by oneself according to existing technologies, so the present invention will not elaborate on its construction method.

[0038] The technical solution of the present invention will be described clearly and completely below in conjunction with specific embodiments. It should be understood that the embodiments described herein are only used to illustrate and explain the present invention and are not used to limit the present invention.

[0039] If no specific techniques or conditions are specified in the following examples, all of them are carried out according to the techniques or conditions described in the literature in the field or according to the product instructions; if the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be obtained commercially.

[0040] Example 1 Construction of Clu-KO mice The Clu gene (gene ID: 12759) is located on chromosome 14 (14D1) and has five transcripts. The fifth transcript (NP_038520.2) contains a complete conserved protein-coding region (CCDS); this transcript encodes 9 exons, with the translation start site ATG located in exon 1 and the translation termination site TGA located in exon 9. The transcript is 1645 bp long and encodes 448 amino acids.

[0041] The present invention selects the fifth transcript design, and based on CRISPR / Cas9 gene editing technology, knocks out the exon E3-E4 region (total length is 2636 bp, the specific base sequence is shown in SEQ ID NO.1), and then constructs Clu-KO mice.

[0042] The present invention comprises the following steps: (1) Design, construct, and in vitro transcribe gRNA according to the design plan.

[0043] gRNA target sequence: gRNA-B1 (matching the gene positive strand sequence): ATGTGTCTGGCAACCGCATCAGG (SEQ ID NO. 2); gRNA-B2 (matching gene positive strand sequence): CCCTACCTGTGAGATTCACTTGG (SEQ ID NO.3).

[0044] (2) Construct a homologous recombination vector (Donor vector).

[0045] According to step (1), the two synthesized single-stranded oligonucleotide gRNA sequences are annealed to form double-stranded DNA, a gRNA expression vector is constructed, and the recombinant plasmid is transformed into DH5a competent cells. The positive clone plasmid is screened and identified by kanamycin resistance and target DNA sequencing, and the correct colony clone is selected. After expansion culture, the plasmid is extracted to prepare an in vitro transcription template.

[0046] Prepare a recombinant plasmid (Donor vector) carrying the homologous region of the target site and the target fragment, transform the recombinant plasmid into DH5a competent cells, screen and identify the positive clone plasmids through ampicillin resistance and sequencing of the inserted fragment, select the correct colony clone, extract and purify the plasmid after expansion culture, and obtain the donor fragment product for injection.

[0047] (3) Obtain Clu-KO mice.

[0048] The CRISPR / Cas9 system and the Donor vector sample were microinjected into the fertilized eggs of female C57BL / 6N background mice, and then the fertilized eggs were transplanted into pseudo-pregnant female mice, and they were allowed to become pregnant and give birth; the F0 generation pups born by the recipient mice were tail-clipped and toe-clipped on days 5-7, and their genomic DNA was extracted for PCR and sequencing to confirm their genotypes. Among them, the genotype identification strategy of the Clu-KO mice of the present invention is as follows: Figure 1 As shown, the PCR primers used include the following two pairs of primers: PCR primer 1 (annealing temperature 60°C): F1: 5'-AACCTCTTGCTCATAGCTGACC-3' (SEQ ID NO.4), R1: 5'-GACCCAAGTTCCCACTGTTCTG-3' (SEQ ID NO.5); PCR primer 2 (annealing temperature 60°C): F1: 5'-AACCTCTTGCTCATAGCTGACC-3' (SEQ ID NO.4), R2: 5'-AGTCACAGCTCAGAAACTCAGG-3' (SEQ ID NO. 6).

[0049] The above PCR primer 1 was used for detection, and the product length was 514 bp (such as Figure 2 ) indicates that the target region has been knocked out (the length of the product without knockout is 3150bp). Figure 1 F2 in A, sequence is GTTCTCTCAGCACACTTCAAGG (SEQ ID NO.11)) for positive animals (such as Figure 2 The mouse numbered 39 in the sequence was sequenced, and the sequencing results are as follows Figure 3 As shown, it is shown that the 2636 bp fragment shown in SEQ ID NO.1 has been deleted.

[0050] Example 2 Construction of Thy1-SNCA;Clu- / - mice In this example, the Clu-KO mice prepared in Example 1 were used to prepare Thy1-SNCA; Clu- / - mice, which specifically included the following steps: (1) Obtain Thy1-SNCA;Clu- / + mice by hybridization.

[0051] After sexual maturity, the Thy1-SNCA-positive F0 mice were mated with Clu- / - background mice (i.e., Clu-KO mice); the F1 mice were separated into cages after 21 days of birth and numbered by tail and toe clipping. Genomic DNA was extracted and PCR reaction was performed using the primers shown in Table 1 (the reaction system and reaction procedure used are shown in Tables 2 and 3) to confirm the genotype.

[0052] Table 1 Primer information used for Thy1-SNCA genotype identification

[0053] Table 2 PCR reaction system used for Thy1-SNCA genotype identification

[0054] Table 3 PCR reaction procedures used for Thy1-SNCA genotype identification

[0055] Some of the identification results of F1 generation mice are as follows Figure 4 As shown, from Figure 4 It can be seen that mice numbered 3, 4, 8, 10, 11, 12, 13, 14, and 17 are all positive (i.e., Thy1-SNCA; Clu- / +).

[0056] (2) Construction of Thy1-SNCA;Clu- / - mice.

[0057] Thy1-SNCA; Clu- / + adult mice were selected and backcrossed with Clu- / - mice to obtain the F2 generation, and the Thy1-SNCA genotype and Clu-KO genotype of the F2 generation mice were then identified to obtain Thy1-SNCA; Clu- / - mice.

[0058] The identification of Thy1-SNCA genotype was the same as step (1). The partial electrophoresis results of F2 generation Thy1-SNCA mice are shown in Figure 5 As shown: mice numbered 1, 3, 4, 5, 10, 11, and 12 are Thy1-SNCA positive, and the remaining numbers are WT.

[0059] Clu-KO genotype identification strategy Figure 1 B and the primers used are shown in Table 4, where primers AB-Clu are Figure 1 F1 in B, A-Cl Figure 1 B in R1, B-Clu Figure 1 R2 in B. The PCR reaction system and reaction procedure used for identification of Clu-KO genotype are shown in Tables 5 and 6, respectively.

[0060] Table 4 Primer information used for Clu-KO genotype identification

[0061] Table 5 PCR reaction system used for Clu-KO genotype identification

[0062] Table 6 PCR reaction procedures used for Clu-KO genotype identification

[0063] When the two pairs of primers shown in Table 4 were used for detection, the homozygote had only one band, namely 514 bp, and the heterozygote had two bands, namely 514 bp and 749 bp. Specifically, the partial electrophoresis detection results of the F2 generation Clu mice in this example are as follows Figure 6 As shown: mice numbered 4, 6, 7, 8, 11, 13, 14, 15, and 16 are Clu- / -, while mice numbered 1, 2, 3, 5, 9, 10, and 12 are Clu- / +.

[0064] Example 3 In this case, pathological tests were performed on Thy1-SNCA mice, Thy1-SNCA;Clu- / + mice, and Thy1-SNCA;Clu- / - mice, including the following steps: (1) Brain tissue sections.

[0065] Animals were perfused transcardially with 4% paraformaldehyde (PFA) in 0.1 M phosphate-buffered saline (PBS, pH 7.4) under isoflurane and chloral hydrate (3%) anesthesia. Brains were harvested, postfixed overnight at 4°C in the same fixative, dehydrated with 30% sucrose in PBS, and serially sectioned on an oscillating microtome (Leica).

[0066] (2) The aggregation of phosphorylated α-syn (p-α-syn) was detected by thioflavin (Ths) staining.

[0067] To detect the co-localization of p-S129α-synuclein and ThS in mouse brain, the sections were incubated with mouse anti-p-S129α-synuclein primary antibody (Abcam, #ab51253, 1:500) at 4°C overnight and washed 3 times with PBS for 5 minutes each time. Then, they were incubated with Alexa Fluor594-labeled anti-mouse antibody for 1 hour at room temperature. After a brief rinse in PBS, the sections were stained with 0.5% ThS in 50% ethanol for 5 minutes, then washed with 50% ethanol and placed in distilled water. Finally, DAPI was used to mount the sections and the slides were covered with glass coverslips and examined under a confocal microscope (Leica Microsystems STELLARIS 5, Germany). This was repeated at least three times.

[0068] The experimental results are as follows Figure 7-9 Shown: At 1 month of age ( Figure 7 ) and 3 months old ( Figure 8 ), there was no significant difference in the phosphorylated α-syn accumulation in the three genotypes of Thy1-SNCA, Thy1-SNCA;Clu- / + and Thy1-SNCA;Clu- / - mice; at 6 months of age ( Fig. 9 ), a large amount of aggregated phosphorylated α-syn appeared in the substantia nigra striatum of Thy1-SNCA;Clu- / - mice. It can be seen that compared with Thy1-SNCA (14M), the Thy1-SNCA;Clu- / - mice provided by the present invention can show obvious PD pathology at an early stage (6M).

[0069] (3) Co-staining of TH and p-α-syn by immunofluorescence.

[0070] The sections were permeabilized in PBS / 0.1% Triton X-100 for 10 minutes and blocked with 4% normal bovine serum in PBS / 0.1% TritonX-100 for 1 hour at room temperature. The sections were then incubated with primary antibodies p-S129 (Abcam, #ab51253, 1:500), TH (CST #58844S) in 2% serum in PBS / 0.1% Triton X-100 overnight at 4°C. The sections were then washed with PBS and incubated with Alexa Fluor 594 and Alexa Fluor 488-conjugated secondary antibodies (i.e., TH secondary antibody and P-α-syn secondary antibody, Invitrogen) for 1 hour at room temperature. After washing with PBS, the sections were incubated with DAPI to stain the nuclei. Images were captured using a Zeiss upright microscope.

[0071] The results are as follows Fig.10As shown: With the increase of age, in 6M Thy1-SNCA;Clu- / - mice, TH was lost in large quantities, and p-α-syn showed obvious aggregation.

[0072] The above results indicate that the Thy1-SNCA;Clu- / - model mice can well replace Thy1-SNCA mice, and compared with Thy1-SNCA mice, the onset of PD-like symptoms is advanced to 6 months of age, which greatly shortens the experimental period.

[0073] Example 4 The motor ability of PD patients is often impaired, often manifested as resting tremor, changes in balance and gait, etc. Therefore, this case tested the behavior of Thy1-SNCA mice, Thy1-SNCA;Clu- / + mice and Thy1-SNCA;Clu- / - mice at different ages.

[0074] Open field test: In the open field test, mice were placed in a 40×40 square grid and allowed to move freely for 10 minutes. The activity trajectory during the period, as well as the number and time of entering the central area, were recorded.

[0075] Rotarod test: In the rotarod test, mice were trained on a rotarod apparatus (MED-Associates) at a speed of 20 rpm for 5 min. After the initial training, mice were tested twice with the speed increasing from 10 rpm to 20 rpm. The training lasted for 3 days, with the speed increasing from 20 rpm to 30 rpm on the second day and from 30 rpm to 40 rpm on the third day. The shedding time was recorded on the fourth day.

[0076] Gait test: In the gait test, the mouse was placed in the gait meter from the left side and allowed to freely walk through the passage to the dark box on the right side. The mice were trained for three consecutive days, and each training session was tested three times in a row. On the fourth day of the test, the trajectory of the mouse through the gait meter was recorded, including the step base, stride length, number of steps, etc.

[0077] Test results such as Figure 11-13As shown: In the open field test, there was no statistically significant difference among the three groups of animals at 1 month and 3 months of age, but there was a difference in the number of times the 3-month-old Thy1-SNCA;Clu- / - mice crossed the central platform, and the difference was more significant at 6 months of age; in the rotating rod test, there was no difference in the grasping ability of Thy1-SNCA;Clu- / - mice at 1 month and 3 months of age, but obvious obstacles appeared at 6 months of age; compared with 6M Thy1-SNCA mice, Thy1-SNCA;Clu- / - mice had significantly smaller step base and stride than Thy1-SNCA mice, and the number of steps increased significantly, which is because PD patients show "small steps"-like signs (shortened stride, increased number of steps) when they have movement disorders.

[0078] The above data show that there is no difference between the three groups of mice in the earlier age period (1-5M); while SNCA-Clu-KO can show significant motor impairment at 6 months of age, which is nearly 8 months earlier than the onset of movement disorders in Thy1-SNCA mice.

[0079] In summary, compared with the traditional PD model, the Thy1-SNCA;Clu- / - mice constructed in the present invention can show obvious PD pathology at 6 months of age, which provides more options for model mice in the study of PD.

[0080] It should be noted that the above embodiments are only part of the embodiments of the present invention rather than all the embodiments, and are only used to illustrate the technical solution of the present invention rather than to limit it. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

Claims

1. A method for constructing a Thy1-SNCA;Clu gene knockout mouse model, characterized in that: The following steps are involved: The F1 generation was obtained by crossing Thy1-SNCA mice with Clu-KO mice, and Thy1-SNCA;Clu- / + mice were identified; The Thy1-SNCA;Clu- / + mice were backcrossed with Clu-KO mice to obtain the F2 generation, and the target genotype mice, namely Thy1-SNCA;Clu- / - mice, were identified.

2. The construction method according to claim 1, characterized in that The Clu-KO mice lack the sequence shown in SEQ ID NO.1 relative to wild-type mice.

3. The construction method according to claim 2, characterized in that: Clu-KO mice were obtained by knocking out the sequence shown in SEQ ID NO.1 in the Clu gene of wild-type mice using the CRISPR / Cas9 system.

4. The construction method according to claim 3, characterized in that: The knockout method comprises: microinjecting the CRISPR / Cas9 system and homologous recombination vector into the fertilized eggs of female C57BL / 6N background mice, then transplanting the fertilized eggs into pseudo-pregnant female mice, waiting for the female mice to become pregnant and give birth, and the recipient mice give birth to F0 generation mice, extracting genomic DNA for identification, and obtaining Clu-KO mice.

5. The construction method according to claim 4, characterized in that: In the CRISPR / Cas9 system, the gRNA target sequences are shown in SEQ ID NO.2 and SEQ ID NO.

3.

6. The construction method according to claim 4, characterized in that: The sequences of the primers used to identify the Clu-KO mice are shown in SEQ ID NO.4 and SEQ ID NO.

5.

7. The construction method according to claim 1 or 2, characterized in that: The primers used to identify the Thy1-SNCA;Clu- / + mice include primers whose sequences are shown in SEQ ID NOs. 7-10.

8. The construction method according to claim 7, characterized in that: The primers used to identify the target genotype mice include primers with sequences shown in SEQ ID NO.4-10.

9. Use of the Thy1-SNCA;Clu gene knockout mouse model constructed according to the construction method of claim 1 in preparing a Parkinson's disease model.

10. Application of the Thy1-SNCA;Clu gene knockout mouse model constructed according to the construction method of claim 1 in studying the function and mechanism of action of the SNCA gene.

Citation Information

Patent Citations

  • Il21 gene knockout mouse model as well as construction method and application thereof

    CN112662669A

  • Construction method of systemic overexpression human alpha-Synn-NLS transgenic mouse

    CN115836667A

  • Construction method and application of'intestine-brain axis' Parkinson's disease mouse model

    CN117210500A

  • Rasd1 gene conditional knockout mouse model, construction method and application

    CN117286184A

  • Development of transgenic model for interventions in neurodegenerative diseases

    WO2003015507A1